Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the addition of tipifarnib to standard letrozole
therapy leads to a better response to treatment for your cancer in comparison to letrozole
plus a placebo. Tipifarnib belongs to a class of drugs called Farnesyl Transferase Inhibitors
(FTI). It blocks proteins that make cancer cells grow.
Phase:
Phase 2
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.